Discordance Between Child‐Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds-Reference-Cited by-同舟云学术

Discordance Between Child‐Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds

Published:2020-07-20 Issue:1 Volume:61 Page:105-115
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Elmeliegy Mohamed¹^ORCID,Yang Derek Z.¹²^ORCID,Salama Engie¹²,Parivar Kourosh¹,Wang Diane D.¹

Affiliation:

1. Global Product Development Pfizer Inc. San Diego California USA

2. Skaggs School of Pharmacy & Pharmaceutical Sciences University of California San Diego San Diego California USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1702

Reference29 articles.

1. Exclusion of Older Patients From Ongoing Clinical Trials for Hematological Malignancies: An Evaluation of the National Institutes of Health Clinical Trial Registry

2. Are We Ready to Include Organ-Impaired Patients in Oncology Trials? A Clinical Pharmacology Perspective on Recent Recommendations

3. FDA.Guidance for industry—pharmacokinetics in patients with impaired hepatic function: study design data analysis and impact on dosing and labeling;2003;https://www.fda.gov/media/71311/download. Accessed June 10 2020.

4. EMA.Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function;2005;https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-pharmacokinetics-medicinal-products-patients-impaired-hepatic-function_en.pdf. Accessed June 10 2020.

5. FDA.Cancer clinical trial eligibility criteria: patients with organ dysfunction or prior or concurrent malignancies;2020;https://www.fda.gov/media/123745/download. Accessed July 13 2020.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug–drug interactions;British Journal of Clinical Pharmacology;2024-01-25

2. Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview;Expert Opinion on Drug Metabolism & Toxicology;2023-10-20

3. Therapeutic Drug Monitoring of Voriconazole in Patients with End-Stage Liver Disease;Therapeutic Drug Monitoring;2023-09-26

4. Incorporation and Performance Verification of Hepatic Portal Blood Flow Shunting in Minimal and Full PBPK Models of Liver Cirrhosis;Clinical Pharmacology & Therapeutics;2023-09-09

5. Assessing Pharmacokinetics in Liver Disease: Challenges and Future Considerations for Classification of Hepatic Dysfunction and Use of In Silico Methods;The Journal of Clinical Pharmacology;2023-04-20